WO2012160519A3 - Método diagnostico que determina la agresividad y pronostico del cáncer papilar de tiroides - Google Patents

Método diagnostico que determina la agresividad y pronostico del cáncer papilar de tiroides Download PDF

Info

Publication number
WO2012160519A3
WO2012160519A3 PCT/IB2012/052572 IB2012052572W WO2012160519A3 WO 2012160519 A3 WO2012160519 A3 WO 2012160519A3 IB 2012052572 W IB2012052572 W IB 2012052572W WO 2012160519 A3 WO2012160519 A3 WO 2012160519A3
Authority
WO
WIPO (PCT)
Prior art keywords
thyroid cancer
papillary thyroid
diagnostic method
aggressiveness
prognosis
Prior art date
Application number
PCT/IB2012/052572
Other languages
English (en)
French (fr)
Other versions
WO2012160519A2 (es
Inventor
Hernán GONZÁLEZ DÍAZ
Alexis KALERGIS PARRA
Original Assignee
Pontificia Universidad Catolica De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Universidad Catolica De Chile filed Critical Pontificia Universidad Catolica De Chile
Publication of WO2012160519A2 publication Critical patent/WO2012160519A2/es
Publication of WO2012160519A3 publication Critical patent/WO2012160519A3/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00Nucleic acid detection characterised by assay method
    • C12Q2561/113Real time assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención provee un método de diagnóstico que permite diferenciar un CPT benigno de un CPT agresivo en un paciente. El método comprende la medición de la expresión de CCR3 en una muestra de tejido tiroideo obtenida del paciente en estudio. CCR3 puede medirse por si solo o en conjunto con otros marcadores. Otros marcadores que pueden cuantificarse para el diagnóstico de pronóstico de CPT corresponden a los receptores de quimokinas CCR7 y CXCR4 u otro tipo de marcadores distintos de receptores de quimokinas. La cuantificación de CCR3 por si sola o en conjunto con la cuantificación de otros marcadores permite comparar los resultados con los valores estándar de dichos marcadores y así determinar si el tumor analizado corresponde a un tumor de características agresivas o benignas. Específicamente, una sobreexpresión de CCR3 se correlaciona con un tumor con parámetros clínicos de agresividad, tal como invasión de la cápsula y metástasis. La invención también provee se refiere a un kit que permite determinar el pronóstico de un CPT, el cual comprende reactivos que permiten la detección de CCR3 en una muestra de tejido tiroideo e instrucciones de uso. En otra modalidad de la invención, se provee un kit para determinar el pronóstico de CPT, el cual comprende reactivos que permiten la detección de CCR3 y de otros marcadores relacionados al CPT. Otros marcadores que pueden cuantificarse para el diagnóstico de pronóstico de CPT corresponden a los receptores de quimokinas CCR7, CXCR4 y/u otro tipo de marcadores distintos de los receptores de quimokinas.
PCT/IB2012/052572 2011-05-24 2012-05-23 Método diagnostico que determina la agresividad y pronostico del cáncer papilar de tiroides WO2012160519A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2011001209A CL2011001209A1 (es) 2011-05-24 2011-05-24 Metodo en vitro para determinar pronostico de un cancer papilar de tiroides que comprende cuantificar, en una muestra, la expresion del receptor de quimiokina ccr3 y donde su sobreexpresion respecto de un valor de referencia indica que el tumor tiene altas probabilidades de invadir la capsula y generar metastasis.
CL1209-2011 2011-05-24

Publications (2)

Publication Number Publication Date
WO2012160519A2 WO2012160519A2 (es) 2012-11-29
WO2012160519A3 true WO2012160519A3 (es) 2013-01-31

Family

ID=47217824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/052572 WO2012160519A2 (es) 2011-05-24 2012-05-23 Método diagnostico que determina la agresividad y pronostico del cáncer papilar de tiroides

Country Status (2)

Country Link
CL (1) CL2011001209A1 (es)
WO (1) WO2012160519A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022133621A1 (es) 2020-12-24 2022-06-30 Pontificia Universidad Católica De Chile Método in vitro para el diagnóstico y predicción de la agresividad de cáncer de tiroides, las posibilidades y tipo de cirugía de precisión para la remoción del tumor en un sujeto; kit; reactivos para conformar dicho kit; uso de los reactivos y uso de marcadores moleculares parte del método

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104717A1 (en) * 2008-07-10 2011-05-05 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104717A1 (en) * 2008-07-10 2011-05-05 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
G0NZALEZ ET AL.: "Altered Chemokine Receptor Expression in Papillary Thyroid Cancer", THYROID, vol. 19, no. 9, September 2009 (2009-09-01), pages 957 - 965 *
GONZALEZ ET AL.: "Altered Chemokine Receptor Expression in Papillary Thyroid Cancer", THYROID, vol. 19, no. 9, September 2009 (2009-09-01), pages 957 - 965 *
YASUOKA ET AL.: "CXCR4 expression in papillary thyroid carcinoma: induction by nitnc oxide and correlation with lymph node metastasis", BMC CANER, vol. 8, 30 September 2008 (2008-09-30), pages 274 - 282 *
YASUOKA ET AL.: "CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis", BMC CANER, vol. 8, 30 September 2008 (2008-09-30), pages 274 - 282 *

Also Published As

Publication number Publication date
WO2012160519A2 (es) 2012-11-29
CL2011001209A1 (es) 2012-02-03

Similar Documents

Publication Publication Date Title
EP3862439A3 (en) Liver cancer detection kit or device, and detection method
EP3967769A3 (en) Lung cancer detection kit or device, and detection method
EP3816303A3 (en) Breast cancer detection kit or device, and method for detecting breast cancer
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
EP3816302A3 (en) Esophageal cancer detection kit or device, and detection method
EP3800253A3 (en) Prostate cancer detection kit or device, and detection method
WO2013022786A3 (en) Microrna biomarkers
EA201590027A1 (ru) Способы детекции заболеваний или состояний
WO2013084002A3 (en) Method for detecting nucleosome adducts
MX364410B (es) Metodo para detectar nucleosomas que contienen nucleotidos.
EP3757225A3 (en) Pancreatic cancer detection kit or device, and detection method
EP3971299A3 (en) Colorectal cancer detection kit or device, and detection method
EP3654036A3 (en) Stomach cancer biomarker and detection method
EP3955004A3 (en) Use of fatty acids in methods for detecting cancer
EP2659268A4 (en) Systems and methods for high accuracy analyte measurement
WO2013030578A3 (en) Method for detecting nucleosomes
BR112016028944A2 (pt) kit ou dispositivo para a detecção de câncer do trato biliar e método de detecção
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2012107841A3 (en) Micro -rna biomarkers for identifying risk of and/or for diagnosing lung tumour and pharmaceutical compositions thereof
WO2010136163A8 (en) Secernin-1 as a marker for cancer
GB201014837D0 (en) Biomarker signatures and uses thereof
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
WO2015059487A3 (en) Detection of cleavage activity of an enzyme
AU2019283856A1 (en) Non-invasive fetal sex determination

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12789393

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12789393

Country of ref document: EP

Kind code of ref document: A2